Editorial: Immune senescence: a key driver of aging and age-related disorders

These four articles within this topic collectively enhance our understanding of immunosenescence, emphasizing its extensive impact on health and disease. Ge et al. reveal significant heterogeneity in lymphocyte subsets between infants and older adults, demonstrating that infants possess higher absolute counts of naï ve and memory T cells, while older adults exhibit increased levels of NK cells. Furthermore, the age-related polarization of the CD4+/CD8+ ratio emerges as a promising biomarker for immunosenescence, offering critical insights to inform age-specific vaccination strategies and immune risk stratification in elderly populations. This shift not only reflects the progressive decline in naive T-cell reserves but also highlights the accumulation of terminally differentiated lymphocytes, which together underscore the systemic dysregulation characteristic of aging immune systems. Building on this, Zhang et al. establish a direct connection between cellular senescence and the pathogenesis of Crohn's disease (CD), identifying senescence-related gene signatures and key hub genes such as STAT3, IL6, and IL1A that contribute to immune dysregulation and intestinal pathology. By elucidating senescence-related gene signatures that delineate molecular subtypes and correlate with immune dysregulation, their research effectively bridges fundamental aging biology with complex chronic inflammatory disorders. Lu et al. demonstrate the clinical utility of a simple systemic immune-inflammation index (SII), derived from routine blood counts, as a robust predictor of all-cause and cancer-specific mortality in older adults (≥60 years). This work underscores the translational potential of simple, inflammation-associated metrics in stratifying mortality risk. Finally, Trebing et al. address a vital methodological consideration in immune aging research by investigating the stability of a composite immune age metric (IMMAX) across the circadian cycle. Their findings validate IMMAX as a reliable biomarker while highlighting the need for standardized sampling timing in immune aging studies.Together, these studies affirm that immunosenescence is not merely a consequence of aging but an active contributor to its pathology, influencing disease susceptibility, progression, and outcomes across diverse contexts.In summary, the convergence of evidence from these studies solidifies immunosenescence as a fundamental aspect of aging biology. The dynamic interplay between cellular senescence, inflammatory pathways, and circadian rhythms elucidated here presents novel opportunities for biomarker development and therapeutic targeting. Future research should prioritize longitudinal studies to unravel causal relationships between immune aging and systemic decline while leveraging omics technologies to identify precision interventions. By harnessing insights from immunosenescence, we can aspire not only to extend healthspan but also to redefine aging as a modifiable process-ultimately transforming our approach to age-related diseases.